HOMBACH ROBERT J. 4

What Happened

• Robert J. Hombach, a director of Seaport Therapeutics (SPTX), received a derivative award on April 30, 2026 covering 12,258 shares. The filing reports an acquisition at $0.00 (no cash paid at grant). This is an equity award (derivative) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-30; Form 4 filed: 2026-05-04 (filed within the standard two-business-day window).
• Instrument: Derivative award (option or similar) covering 12,258 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Vesting/other footnote: The shares underlying this option shall vest in full on April 30, 2027, subject to Hombach’s continued service on that date (Footnote F1).
• Transaction code: A (grant/award).

Context

• This was a granted equity award, not a cash purchase or sale. The award does not appear to be immediately exercisable — it vests in full one year from the grant date, contingent on continued service.
• Awards like this are common for directors and are compensation-related; they do not by themselves indicate buying or selling sentiment by the insider.